Arvinas and Pfizer announce initial Phase 1b Data from the TACTIVE-U sub-study of Vepdegestrant in…
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5 per cent;…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Arvinas
PROTACs oncology market to hit $3.7 billion by 2030 despite lack of approved therapies: GlobalData
The PROTAC oncology market is projected to capture $3.7 billion by 2030 Proteolysis targeting chimeras (PROTACs) are a…